#United States #Denver #financial results #DaVita Inc. #Q3 2026

DaVita Inc. Third Quarter 2026 Financial Results

DaVita Inc. (NYSE: DVA) unveiled its financial performance for the third quarter that concluded on September 30, 2026. The company's report demonstrated solid growth, providing insight into its operational effectiveness amidst the challenging healthcare landscape.

Financial Highlights

For the quarter, DaVita Inc. recorded a consolidated revenue of $3.578 billion, reflecting an increase driven by the stabilization of patient care services. The company reported an operating income of $499 million, with an adjusted operating income amounting to $561 million. Moreover, the diluted earnings per share stood at $3.40, while the adjusted diluted earnings per share was slightly higher at $3.82. With strong operating cash flow of $519 million, the company generated free cash flow of $276 million during this period.

Significantly, DaVita repurchased 0.6 million shares of its common stock at an average price of $186.21 per share, demonstrating its commitment to returning value to shareholders.

Detailed Financial Metrics

The key financial metrics for the quarter are summarized as follows:

• - Net Income: $223 million
• - Adjusted Net Income: $250 million
• - Operating Margin: 14.0% (adjusted operating margin at 15.7%)
• - Revenue per Treatment: $415.25
• - Patient Care Costs per Treatment: $280.22

In terms of patient service, DaVita managed 7,329,644 total dialysis treatments for the quarter, averaging 92,780 treatments per day, which reflects a minimal daily growth of 0.1% compared to the preceding quarter. The normalized growth in non-acquired treatments was reported at 0.4% year-over-year.

Operations Overview

As of September 30, 2026, DaVita provided dialysis services to approximately 298,100 patients across 3,269 outpatient dialysis centers. This includes 2,671 centers in the U.S. and 598 centers internationally. Such extensive network connectivity ensures that DaVita remains a front-runner in the renal healthcare space.

The integrated kidney care (IKC) program expanded significantly, managing about 80,800 patients within risk-based payment arrangements, representing an annualized medical spend of approximately $6.4 billion. An additional 3,100 patients were enrolled in other integrated care arrangements.

Operational Efficiency Insights

The financial reporting highlighted some operational challenges and cost adjustments:

• - Patient Care Costs: Increased primarily due to heightened medical supplies expenses. Year-to-date, the costs are further influenced by overall compensation expenses and other health benefit related costs, which underlined the ongoing battle with inflation in health service provisions.
• - General and Administrative Expenses: These were slightly reduced in the quarter, mainly attributed to lower professional fees, though increased IT-related expenditures posed a challenge due to past cybersecurity incidents.
• - Goodwill and Asset Impairments: The quarter also reflected a $62 million non-cash impairment charge related to DaVita’s business in China, indicating the complexities of international operations amid various global economic conditions.

Looking Ahead

Moving forward, DaVita’s guidance for 2026 suggests strategic measures to bolster earnings efficiency and improve operational metrics. The management team remains cautiously optimistic, emphasizing a focus on sustaining revenue growth and managing costs effectively.

Conclusion

DaVita Inc.'s Q3 results underscore its resilience and adaptability in the dynamic healthcare market. With ongoing strategic initiatives and a reaffirmed commitment to integrated kidney care, DaVita is poised for continued growth as it aims to enhance patient outcomes while ensuring shareholder value. A conference call detailing these results will be held on October 29, 2026, at 5:00 PM ET. Stakeholders are encouraged to participate and engage with the company’s leadership team for further insights into future operations and financial strategy.